anti-HLA-A02 TRuC Treg-cell therapy (TCR2 Therapeutics)

N/A

Report date: 2025/01/26 19:06:31

Base Information

Drug Nameanti-HLA-A02 TRuC Treg-cell therapy (TCR2 Therapeutics)
Drug Alias NameTRuC Treg cells targeting HLA-A02 (TCR2 Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsRejection of organ transplantationInflammationGraft vs Host Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTcr2 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTcr2 Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationInflammationGraft vs Host Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A